Published in
Ivyspring International Publisher, Journal of Cancer, p. 81
DOI: 10.7150/jca.2.81
Links
- ORCID
- Ivyspring International Publisher | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [citeseerx.ist.psu.edu] | PDF
- [citeseerx.ist.psu.edu] | PDF
- [www.jcancer.org] | PDF
Tools
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
Journal article published in 2011 by
James M. Reuben,
Luis H. Camacho,
Aung Naing,
Hui Gao,
Claire Verschraegen,
Bang-Ning Lee,
Evan N. Cohen 
,
Saneese Stephen,
Joann Aaron,
Jennifer Wheler,
David Hong,
Razelle Kurzrock
,
Saneese Stephen,
Joann Aaron,
Jennifer Wheler,
David Hong,
Razelle Kurzrock
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Purpose: Sodium stibogluconate (SSG), a small molecule inhibitor of protein tyrosine phosphatases, combined with IFN-alpha-2b (IFN-α) inhibited solid tumor cell line growth in vitro. We conducted a phase I clinical trial with SSG plus IFN-α in advanced cancer patients to assess tolerance, maximum tolerated dose (MTD) and immune system effects.